重大事件
外國發行人報告
6-K
2026-07-01
Haleon 提交6-K 更新截至6月底總投票權及已發行股本
AI 繁中摘要
Haleon plc (LSE/NYSE: HLN) 於2026年7月1日向美國證監會提交6-K表格，更新截至2026年6月30日的總投票權及股本資料。
截至2026年6月30日，公司已發行普通股總數為 8,820,906,422 股（每股面值0.01英鎊），其中 12,006,714 股由公司持有作庫存股。因此，附有投票權的普通股數目為 8,808,899,708 股。
此數字將作為分母，供股東及其他須履行披露責任的人士計算其在公司權益的持股比例，以確定是否需要根據英國金融行為監管局（FCA）的披露指引及透明度規則作出通知。
📋 有意義的權益變動通知可電郵至 [email protected]。
本次公告僅為例行股本更新，並無提及管理層展望或業績變動，對投資者的直接影響主要見於確保股東通知義務的合規性。
展開英文正文
6-K
1
a4855k.htm
TOTAL VOTING RIGHTS AND CAPITAL
a4855k
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒
Form
40-F ☐
EXHIBIT INDEX
Exhibit
Number
Description
99.1
01 July
2026 - “Total Voting Rights and
Capital”
99.1
Haleon plc: Total Voting Rights and Capital
01 July 2026: As
at 30 June 2026 the total number of shares issued by Haleon plc
("Haleon" or the "Company") is 8,820,906,422 ordinary
shares of £0.01 each, of which 12,006,714 are held as treasury
shares.
Therefore, the number of ordinary shares with voting rights is
8,808,899,708 and this figure should be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Notifiable interests in Haleon may be sent to: [email protected]
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
HALEON PLC
(Registrant)
Date:
July 01, 2026
By:
/s/
Amanda Mellor
Name:
Amanda
Mellor
Title:
Company
Secretary